Revumenib is named as a drug or biological intervention in 4 clinical trials in our USA, UK and Ireland trial registers, 3 of which are recruiting. Lead sponsors include Syndax Pharmaceuticals (3) and Stichting Hemato-Oncologie voor Volwassenen Nederland (1). Registered phases: Phase 3, Phase 1 and Phase 1/2. Conditions studied include Acute Myeloid Leukemias; Acute Myeloid Leukemia, Adult; Acute Myeloid Leukemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML Acute Myeloid Leukemia, Adult |
Phase 3 | Recruiting |
| NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation (ClinicalTrials.gov ↗) Acute Myeloid Leukemias |
Phase 3 | Recruiting |
| NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia |
Phase 1/2 | Recruiting |
| NCT06226571 | A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias (ClinicalTrials.gov ↗) Acute Myeloid Leukemias |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Myeloid Leukemias | 2 |
| Acute Myeloid Leukemia, Adult | 1 |
| Acute Myeloid Leukemia | 1 |
| Acute Lymphoblastic Leukemia | 1 |
| Mixed Lineage Acute Leukemia | 1 |
| Mixed Phenotype Acute Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Syndax Pharmaceuticals | 3 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 1 |
| Register | Revumenib trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in UK | 2 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Revumenib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Revumenib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.